Q-omics provides the consensus-scored PROSER2 profile across patient tissues and cancer cell-line models. PROSER2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PROSER2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PROSER2 RNA expression shows 18,195 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where PROSER2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROSER2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROSER2 survival associations across molecular data types. PROSER2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROSER2 RNA expression–survival associations across cancer types. High PROSER2 expression shows unfavorable associations in UVM, PAAD, ACC, KIRP and HNSC, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PROSER2 RNA expression.
This table summarizes PROSER2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PROSER2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROSER2 shows lower tumor expression in KIRC and KICH and higher tumor expression in BLCA, HNSC, UCEC and STAD. The KIRC box plot shows higher PROSER2 RNA expression in normal versus tumor tissue (log2 FC = −1.223, t-test p < 0.001).
This table shows molecular features associated with PROSER2 in patient tissues and cancer cell lines. In patient samples, PROSER2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PROSER2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
